Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas and FibroGen Receive Approval of EVRENZO« in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis

11/27/2020 | 02:02am EDT

Astellas Pharma Inc. and FibroGen, Inc. announced that Japan'sMinistry of Health, Labour and Welfare (MHLW) approved EVRENZO® (roxadustat) for the treatment of anemia of chronic kidney disease (CKD) in adult patients not on dialysis. This marks the second approval in Japan for roxadustat through the Astellas and FibroGen collaboration, after the therapy was approved and launched for use in adult patients with anemia of CKD on dialysis last year. This approval is based on results obtained from three clinical studies in more than 500 Japanese patients with anemia of CKD not on dialysis. The first, an open-label Phase 3 conversion study versus active comparator, darbepoetin alfa, met the primary efficacy endpoint of non-inferiority and continued to demonstrate maintenance of hemoglobin (Hb) levels over time. Roxadustat was generally well tolerated, and the safety profile was comparable with that of darbepoetin alfa. The other two studies (one Phase 3 and one Phase 2) support the safety and efficacy of roxadustat in erythropoiesis-stimulating agent (ESA)-untreated patients. The approval of the supplementary New Drug Application (sNDA) for roxadustat in Japan for the treatment of anemia of CKD in adult patients not on dialysis triggers a milestone payment of $15 million by Astellas to FibroGen. As a first-in-class orally administered inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase (PH), roxadustat increases Hb levels through a mechanism of action that is different from that of traditional ESAs. As a HIF-PH inhibitor, roxadustat activates the body's natural protective response to reduced oxygen levels in the blood. This response involves the regulation of multiple, coordinated processes that lead to the correction of anemia.


ę S&P Capital IQ 2020
All news about ASTELLAS PHARMA INC.
02:12aASTELLAS PHARMA : Science-based Exercise at Home with Fit-eNce HomeTM Pilot Sales Begins T..
PU
09/20ASTELLAS PHARMA : ' and Pfizer's XTANDI« (enzalutamide) Reduced Risk of Death by 34% in Me..
PU
09/20ASTELLAS PHARMA : ' and pfizer's xtandi (enzalutamide) reduced risk of death by 34% in men..
AQ
09/09ASTELLAS PHARMA : Updates “Contact for Potential Acquisition of ' R&D Programs&rdquo..
PU
09/02ASTELLAS PHARMA : Nitto, and M. Heart Partnering for ECG testing service
PU
09/01Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked My..
CI
08/31ASTELLAS PHARMA : Announces Personnel Changes
PU
08/30ASTELLAS PHARMA : Launches its Corporate Website's New Modalities~Approach for Cell..
PU
08/20SECTOR UPDATE : Health Care Stocks Mixed Premarket Friday
MT
08/20FIBROGEN : Receives $120 Million Milestone Payment With Approval of Evrenzo in Europe
MT
More news
Financials
Sales 2022 1 325 B 12 129 M 12 129 M
Net income 2022 194 B 1 780 M 1 780 M
Net cash 2022 478 B 4 372 M 4 372 M
P/E ratio 2022 17,7x
Yield 2022 2,67%
Capitalization 3 476 B 31 819 M 31 823 M
EV / Sales 2022 2,26x
EV / Sales 2023 1,90x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 876,00 JPY
Average target price 2 451,54 JPY
Spread / Average Target 30,7%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.17.69%31 975
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000